8-K: Adagio Medical Completes FULCRUM-VT Enrollment

Adagio Medical Holdings, Inc. announced the completion of enrollment for its FULCRUM-VT Pivotal U.S. FDA IDE study for its vCLAS Cryoablation System.

Summary

• Adagio Medical Holdings, Inc. completed enrollment for its FULCRUM-VT Pivotal U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) study.
• The study evaluates the vCLAS Cryoablation System for ablation of monomorphic ventricular tachycardia (MMVT).
• The vCLAS System, built on proprietary ultra-low temperature cryoablation (ULTC) technology, has been granted Breakthrough Device Designation by the FDA.
• This is the first VT-specific ablation technology to complete enrollment in a pivotal IDE study in the United States.
• The FULCRUM-VT study enrolled 208 patients across 20 centers in the United States and Canada.
• The primary efficacy endpoint is six-month freedom from recurrent MMVT in the absence of new or increased doses of pre-ablation antiarrhythmic drugs.
• Results from FULCRUM-VT will be used to support a pre-market approval (PMA) application for the vCLAS System.
• Adagio's vCLAS System is commercially available for MMVT treatment in Europe and select other geographies, but is limited to investigational use in the United States.

Sentiment

Score: 8

Explanation: The completion of enrollment for a pivotal FDA study, especially for a Breakthrough Device, is a significant positive milestone for a medical device company. The rapid enrollment further underscores the market need and potential of the technology. While no financial data is provided, this operational achievement de-risks the regulatory pathway and enhances future commercial prospects.

Positives

• Completed enrollment for the FULCRUM-VT Pivotal U.S. FDA IDE study, a critical regulatory milestone.
• The vCLAS System has FDA Breakthrough Device Designation, indicating potential for significant clinical benefit.
• Enrollment for the FULCRUM-VT pivotal study was completed in only 11 months, demonstrating strong market need and positive early experiences with the ULTC technology.
• The vCLAS System is the first VT-specific ablation technology to complete enrollment in a pivotal IDE study in the U.S., positioning Adagio as a leader in this niche.
• The ULTC technology is already commercially available for MMVT treatment in Europe and other select geographies.
• The technology has the potential to address the underserved population of patients with ventricular tachycardia.

Negatives

• The vCLAS System is currently limited to investigational use in the United States, awaiting PMA approval.
• No financial results or updates were provided in this filing.

Risks

• Forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied.
• Risks regarding Adagio's business are detailed in its Securities and Exchange Commission (SEC) filings, including its Annual Report on Form 10-K for the full-year ended December 31, 2024, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Future Outlook

Adagio anticipates completing the PMA process for the vCLAS System by year-end 2026, consistent with previous guidance, with the goal of bringing its ULTC technology to the underserved population of VT patients.

Management Comments

• "Adagio's vCLAS System is the first VT-specific ablation technology to complete enrollment in a pivotal IDE study in the United States." Dr. Atul Verma, Director of Cardiology at McGill University Health Centre and FULCRUM-VT co-principal investigator.
• "Our center has had the unique opportunity to participate in both the earlier CRYOCURE-VT study, which supported CE Mark in Europe, and the FDA IDE study in the U.S., and we are firm believers in the many advantages of Adagio's ULTC as a potential game-changing technology to treat patients with drug-refractory ventricular tachycardia." Dr. Atul Verma.
• "The fact that the FULCRUM-VT pivotal study completed enrollment in only 11 months speaks volumes to both the market need for a purpose-built VT ablation technology and the positive early experiences with Adagio's ULTC at the top VT ablation programs that participated in the study." Dr. Rod Tung, Chief of the Division of Cardiology at Banner University Medical Center and study co-principal investigator.
• "I would like to thank the FULCRUM-VT investigators and research staff who have done an outstanding job working with our team over the last several months to achieve this critical milestone." Todd Usen, Chief Executive Officer of Adagio.
• "We are also grateful to the FDA for our collaborative relationship." Todd Usen.
• "We are excited for the potential to bring our ULTC technology to the underserved population of VT patients and we anticipate completion of the PMA process for the vCLAS System by year-end 2026, consistent with previous guidance." Todd Usen.

Industry Context

The completion of enrollment for a pivotal U.S. IDE study for a VT-specific ablation technology addresses a significant unmet medical need, as current VT ablation options often rely on catheters and energy sources originally designed for atrial arrhythmias. This positions Adagio as a potential leader in purpose-built solutions for ventricular tachycardia, a condition notoriously difficult to treat and study.

Comparison to Industry Standards

• The vCLAS System is noted as the first VT-specific ablation technology to complete enrollment in a pivotal IDE study in the United States, differentiating it from existing technologies primarily developed for atrial arrhythmias.
• The FULCRUM-VT study completed enrollment in only 11 months, which is highlighted as significantly faster than typical VT ablation studies, which were "notoriously difficult and slow to enroll." This suggests a strong positive reception and perceived efficacy compared to historical benchmarks.
• The earlier CRYOCURE-VT study supported CE Mark in Europe, indicating a level of regulatory acceptance and commercialization outside the U.S. that other emerging technologies might not yet have achieved.

Stakeholder Impact

• Shareholders: Positive impact due to progress towards FDA approval and potential future commercialization in the U.S., de-risking the investment.
• Patients: Potential for a new, purpose-built treatment option for drug-refractory monomorphic ventricular tachycardia, addressing an underserved population.
• Medical Professionals: Provides a new, potentially game-changing tool for treating complex cardiac arrhythmias, supported by positive early experiences.

Next Steps

• Analysis of FULCRUM-VT study results.
• Submission of a pre-market approval (PMA) application for the vCLAS System to the FDA.
• Completion of the PMA process for the vCLAS System by year-end 2026.

Key Dates

Recommendation

The successful and rapid completion of enrollment for a pivotal FDA IDE study for a Breakthrough Device is a major de-risking event for Adagio Medical. This milestone significantly advances the company towards potential U.S. market approval for a purpose-built technology addressing a high unmet medical need in ventricular tachycardia. While commercial success is not guaranteed, this regulatory progress, coupled with existing CE Mark approval in Europe, indicates strong potential for future revenue growth and market penetration, making it an attractive long-term investment.

Keywords

Adagio Medical, ADGM, FULCRUM-VT, vCLAS Cryoablation System, Ventricular Tachycardia, VT ablation, Cryoablation, Ultra-Low Temperature Cryoablation, ULTC, FDA IDE study, PMA approval, cardiac arrhythmias, medical device, Breakthrough Device Designation